EASL has published several reports on liver disease in Europe and is commissioning work on future publications.
Considering most liver cancer cases are caused by viral hepatitis, 54% of liver cancer diagnoses are due to HBV infection and 31% to HCV infection1, EASL would like to see the new European Code Against Cancer provide more comprehensive information on the link between viral hepatitis and cancer.
Read More
Geneva, June 2023: The aim of this European Association for the Study of the Liver (EASL) policy statement is to: 1. Urge policy-makers to reduce health-related, social and economic harms caused by alcohol by implementing evidence-based policies to reduce alcohol consumption in the general population, and 2. Empower health professionals, especially those working with liver…
Read More
Geneva, 18 April 2023: This EASL Policy Statement about risk-based surveillance for hepatocellular carcinoma (HCC) among patients with cirrhosis demonstrates how risk-based surveillance has the potential to reduce not only deaths from HCC but also the costs of offering HCC surveillance.
Read More
EASL supports in full the consultation responses provided by Scottish Health Action on Alcohol Problems (SHAAP) and Alcohol Focus Scotland to the Scottish Government initiative to Restricting alcohol advertising and promotion.
Read More
EASL welcomes the initiative of the European Commission to propose actions to increase the uptake of vaccination against the Hepatitis B virus and human papillomaviruses. In its response, EASL calls on the EU Member States to prioritise key actions, especially to upscale HBV vaccination rates, by encouraging Member States to implement stronger national strategies and…
Read More
The European Association for the Study of the Liver (EASL) welcomes the European Commission’s initiative to build an EU Cancer Inequalities Registry and recommends the inclusion of inequalities in liver cancer and in its key causes: liver cirrhosis due to viral hepatitis, alcohol-related liver disease (ARLD), or non-alcoholic fatty liver disease (NAFLD). Around 90% of…
Read More
EASL endorsed a Joint Statement, together with other 15 organisations. EASL welcomes the European framework for action on alcohol 2022–2025 and endorses the evidence-based language of the Framework and supports the six areas for priority action.
Read More
International organisations representing doctors, cancer patients, young people, researchers, public health and development advocates across Europe issued the Oslo Declaration- a call for policy action to curb alcohol harm. Europe is the heaviest alcohol consuming region in the world. The burden of alcohol related harms to individuals, families, communities and society is enormous. Half of…
Read More
Geneva, 27 May 2022: In Europe, the number of deaths from liver cancer has doubled in the past 30 years. Screening for liver cancer with an ultrasound examination every six months is an established method to reduce mortality resulting from liver cancer. EASL guidelines recommend that screening for liver cancer is offered to patients with…
Read More
EASL submitted a written statement at the 72nd Session of the WHO Regional Committee for Europe taking place 12- 14 September 2022 in Tel Aviv, Israel. EASL strongly supports the efforts for the prevention and control of Noncommunicable Diseases in the WHO European Region 2016-2025 and asked WHO Europe to incorporate the NAFLD into their…
Read More